anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
RATIONALE AND OBJECTIVES: The current clinical standard for functional imaging of patients with lung ailments is nuclear medicine scintigraphy and Single Photon Emission Computed Tomography (SPECT) which detect the gamma decay of inhaled radioactive tracers. Hyperpolarized (HP) Xenon-129 MRI (XeMRI) of the lungs has recently been FDA approved and provides similar functional images of the lungs with higher spatial resolution than scintigraphy and SPECT. Here we compare Technetium-99m (99mTc) diethylene-triamine-pentaacetate scintigraphy and SPECT with HP XeMRI in healthy controls, asthma, and chronic obstructive pulmonary disorder (COPD) patients.
MATERIALS AND METHODS: 59 subjects, healthy, with asthma, and with COPD, underwent 99mTc scintigraphy/SPECT, standard spirometry, and HP XeMRI. XeMRI and SPECT images were registered for direct voxel-wise signal comparisons. Images were also compared using ventilation defect percentage (VDP), and a standard 6-compartment method. VDP calculated from XeMRI and SPECT images was compared to spirometry.
RESULTS: Median Pearson correlation coefficient for voxel-wise signal comparison was 0.698 (0.613-0.782) between scintigraphy and XeMRI and 0.398 (0.286-0.502) between SPECT and XeMRI. Correlation between VDP measures was r = 0.853, p < 0.05. VDP separated asthma and COPD from the control group and was significantly correlated with FEV1, FEV1/FVC, and FEF 25-75.
CONCLUSION: HP XeMRI provides equivalent information to 99mTc SPECT and standard spirometry measures. Additionally, XeMRI is non-invasive, hence it could be used for longitudinal studies for evaluating emerging treatment for lung ailments.
1,177,095. Oxalic acid diarylamides. CIBA Ltd. 7 Feb., 1967 [7 Feb., 1966], No. 28783/68. Divided out of 1,177,094. Heading C2C. The invention comprises compounds of the formula where R 1  and R 2  are alkyl of 1-18 carbon atoms which may be substituted by Cl, OH, alkoxy of 1-4 carbon atoms, carboxy, CN, carboxylic acid amide or carboxylic acid alkyl ester of up to 12 carbon atoms in the alkyl moiety, alkenyl of 3-4 carbon atoms, benzyl which may be substituted by Cl or alkyl, aliphatic acyl of up to 18 carbon atoms or benzoyl which may be substituted by Cl or alkyl of 1-4 carbon atoms, R 3  and R 4  are alkyl of 1-12 carbon atoms, halogen, haloalkyl, sulphonic acid, phenyl or phenylalkyl whose alkyl residue contains 1-4 carbon atoms, or two orthopositioned residues R 3  and/or R 4  together form a fused-on six-membered aromatic carbocyclic ring, m and n are 1 or 2, p and q are 1-3, m+(n-1) = or 2, each of the two ring systems containing at most 3 substituents apart from the amide group, the substitutents being so constituted that the molecule is asymmetrical. The compounds are prepared by condensing compounds of the formulµ where A 1  is hydroxy, halogen, alkoxy of 1-12 carbon atoms, benzyloxy or phenoxy and 2 is H or R 2  at 50-250 C. and the free hydroxy groups are blocked by subsequent etherification or acylation.
Tinnitus is a heritable, highly prevalent auditory disorder treated by multiple medical specialties. Previous GWAS indicated high genetic correlations between tinnitus and hearing loss, with little indication of differentiating signals. We present a GWAS meta-analysis, triple previous sample sizes, and expand to non-European ancestries. GWAS in 596,905 Million Veteran Program subjects identified 39 tinnitus loci, and identified genes related to neuronal synapses and cochlear structural support. Applying state-of-the-art analytic tools, we confirm a large number of shared variants, but also a distinct genetic architecture of tinnitus, with higher polygenicity and large proportion of variants not shared with hearing difficulty. Tissue-expression analysis for tinnitus infers broad enrichment across most brain tissues, in contrast to hearing difficulty. Finally, tinnitus is not only correlated with hearing loss, but also with a spectrum of psychiatric disorders, providing potential new avenues for treatment. This study establishes tinnitus as a distinct disorder separate from hearing difficulties.
FORTAMET® is contraindicated in patients with:

  1. Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see WARNINGS and PRECAUTIONS).
  2. Known hypersensitivity to metformin.
  3. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.



FORTAMET® should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function (see also PRECAUTIONS).
The utility model discloses a recombinant fibronectin functional short body and a preparation method thereof. Recombinant fibronectin functional shortbodies include fusion polypeptides of a cell-binding peptide, fibronectin collagen-binding protein binding domain sequence, and a bungarotoxin antibacterial peptide linked sequentially; the amino acid sequence of the fusion peptide is shown as SEQ ID NO. 1; the amino acid sequence of the cell binding peptide is shown as SEQ ID NO. 2; the amino acid sequence of the domain sequence of the fibronectin-binding collagen is shown as SEQ ID NO. 3; the amino acid sequence of the bungarotoxin antibacterial peptide is shown as SEQ ID NO. 4. The recombinant fibronectin functional short body and the preparation method thereof can effectively solve the defects of small molecular weight, short half-life period and easy inflammation and infection during use of fibronectin, and are beneficial to the application in the aspects of cell absorption and growth promotion, wound healing and antibiosis.
Subject patients are above 20 in age who are hospitalized in our hospital or outpatients with arrhythmia symptoms after the clinical research approval. The sinus rhythm electrocardiogram at the time of the patient's participation in the study is put into the artificial intelligence prediction algorithm, and the risk stratification results are blinded and are not informed to both the research director and the subjects. For the low-risk group, after attaching the wearable electrocardiogram to the subject, the electrocardiogram recorded a week later is analyzed to confirm the occurrence of atrial fibrillation.
By individually metering and dispensing specific volumes and/or weights of each component of a dosage, an amount of the components for each dose is secured with very high accuracy. A method for dosing a pharmaceutical product in a sealed container, such as, for example, a packet, sachet, blister pack, or other unit dose form. The dosage may include a first component that is a thickening agent and a second component that is an active ingredient. The thickening agent serves as a carrier that allows the active ingredient to dissolve in the mouth and be swallowed without the administration of water. The method includes providing the first component by measuring the volume or weighing the mass of the first component and measuring the volume or weighing the mass of the second component. Subsequent components may also be individually measured or weighed before being added to a package.
The present invention discloses tea cream sugar which is composed of raw materials according to proportioning (weight part) of 65 to 80 of white sugar and/or crystal sugar, 5 to 8 of honey, 7 to 10 of peppermint oil, 3 to 5 of borneol, 2 to 5 of katsumada galangal seed or round cardamon seed, 3 to 5 of amomun fruit, 2 to 4 of pearl powder, 4 to 7 of galangal and 5 to 7 of liquorice. The tea cream sugar provided by the present invention has no substances of chemical additives, preservatives, etc. and belongs to a natural green functional food. To users, the edible requirements for sweets are satisfied, and simultaneously, the common uncomfortableness can be suppressed or relieved. Various ingredients, such as liquorice, cardamom, borneol, amomun fruit, black bean, areca, galangal, honey, etc., in the tea cream sugar are frequently foods or seasonings or medicines or foods for people to eat at ordinary times. Thus, the present invention has no side effect when the tea cream sugar is eaten for a long time, and the health care function can be obtained. The food product is the medicine when people are sick, and is sugar when people are not sick, and the medicine and the food have isogeny.
Psychoeducation placebo control intervention: 6 weekly online sessions composed of educational videos (ca. 20 minutes) on aspects related to pregnancy and sleep.
PURPOSE:To obtain a whitening agent consisting of a spiroether compound and having action suppressing melanogenesis and decreasing and diminishing melanogenesis after irradiation of ultraviolet rays and to obtain a skin external preparation containing the whitening agent. CONSTITUTION:This whitening agent contains a spiroether compound expressed by the formula (the wavy line represents that the binding state may be either one of Z or E). This skin external preparation is prepared by blending a compound of the formula in an amount of 0.000001 to 10wt.%, preferably 0.00001-5wt.%. The compound of the formula has action suppressing melanogenesis and decreasing or diminishing melanization produced by irritation of ultraviolet rays and the skin external preparation obtained by blending the compound has excellent whitening effect and preventing and treating effect on stain and ephelis due to sunburn, etc., and the preparation has high safety. The compound of the formula is obtained by extracting from a plant of the genus Matricaria of the family Compositae, e.g. chamomile. The skin external preparation can be prepared in a formulation such as cream, milk lotion, toilet lotion, foundation, pack, lotion, gel, solution or stick.
Spiral ganglion neurons (SGNs) transmit sound signals received by hair cells to the auditory center to produce hearing. The quantity and function are important for maintaining normal hearing function. Limited by the regenerative capacity, SGNs are unable to regenerate spontaneously after injury. Various neurotrophic factors play an important role in the regeneration process. Neuritin is a neurite growth factor that plays an important role in neural plasticity and nerve injury repair. In this study, we used bioinformatics analysis to show that neuritin was negatively correlated with cochlear damage. Then, we aimed to establish a cochlear spiral ganglion-specific sensorineural deafness model in gerbils using ouabain and determine the effects of exogenous neuritin protein in protecting damaged cochlear SGNs and repairing damaged auditory nerve function. The provides a new research strategy and scientific basis for the prevention and treatment of sensorineural deafness caused by the loss of SGNs. We were discovered that neuritin is expressed throughout the development of the gerbil cochlea, primarily in the SGNs and Corti regions. The expression of neuritin was negatively correlated with the sensorineural deafness induced by ouabain. In vitro and in vivo revealed that neuritin significantly maintained the number and arrangement of SGNs and nerve fibers in the damaged cochlea and effectively protected the high-frequency listening function of gerbils.
Many autistic individuals with intellectual disability experience anxiety, and for those who use few or no words, anxiety may present as behaviour that challenges, such as self-injury and avoiding anxiety-provoking situations. Families report difficulty accessing support from services for autistic individuals experiencing anxiety. Moreover, once receiving support, effective interventions for autistic people with intellectual disability are limited. We completed individual and group discussions with 16 caregivers of autistic people with intellectual disability, to (a) explore their experiences of accessing services for anxiety and/or behaviour that challenges for their child; and (b) understand what matters to caregivers when developing interventions that have been designed for them and the autistic individual with intellectual disability that they support. Caregivers reported that services, in their experience, did not deliver the support that they expected, and that they often needed to 'fight' for support. Caregivers considered services and families working together, the inclusion of peer support, and families being offered interventions that are flexible to individual circumstances to be important. These considerations are valuable for clinicians and researchers developing interventions and aiming to improve outcomes for autistic people with intellectual disability and their families.
The term occluding vasculopathies covers a large number of different conditions. These often manifest as skin ulcers. Occluding vasculopathies should be considered in the differential diagnosis of leg ulcers. The term "occlusive vasculopathies" encompasses pathophysiologically related entities that share structural or thrombotic obliteration of small cutaneous vessels. In this article, we will focus on livedoid vasculopathy with and without antiphospholipid syndrome and calciphylaxis with differentiation from hypertonic leg ulcer as the most relevant differential diagnoses of leg ulcer. The term also includes vascular occlusion, for example due to oxalate or cholesterol embolism, and septic vasculopathy. This often leads to acral ulceration and is therefore not a differential diagnosis with classic leg ulcers. It will not be discussed in this article. Occlusive vasculopathy may be suspected in the presence of the typical livedo racemosa or (non-inflammatory) retiform purpura as a sign of reduced cutaneous perfusion in the wound area. Inflammatory dermatoses, especially vasculitides, must be differentiated. This is achieved by histopathological evaluation of a tissue sample of sufficient size and depth taken at the appropriate time. In addition, specific laboratory parameters, particularly coagulation parameters, can support the diagnosis.
NEW MATERIAL:The diphenylpyridine compound of formula I (R<1> is lower alkylcarbamoyl substituted with heterocyclic group; R<2> is nitro; R<3> is lower alkyl, lower alkoxy or halogen; R<4> is lower alkyl) and its salt. EXAMPLE:2-Methyl-3-(2-morpholinoethylcarbamoyl)-4-(3-nitrophenyl)-6-ph enylpyri dine. USE:Useful as a remedy for ischemic diseases. It can be administered orally or parenterally. PREPARATION:The compound of formula I can be produced e.g. by reacting a compound of formula II (R<3>a is H, lower alkyl, lower alkoxy or halogen) with a compound of formula III or its salt. The starting compounds of formula II and formula III are novel and the compound of formula III can be synthesized by using a compound of formula IV and a compound of formula V as starting raw materials. The compound of formula II is derived from the compound of formula VI and the compound of formula III.
A novel gene is provided which is associated with audiogenic seizures in mice. The disclosed gene is known as the Monogenic Audiogenic Seizure-susceptible gene or massl, with a product designated MASS 1. Nucleic acid molecules that encode for MASS I have been identified and purified. Mammalian genes encoding MASSI are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS I protein. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated. The invention further relates to a hearing impairment associated with the Frings MASS1 mutation. More specifically, the invention characterizes a moderate and non-progressive hearing impairment which leads to the development of audiogenic seizures.
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.
This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
BACKGROUND: Early prognosis evaluation is crucial for decision-making in cardiogenic shock (CS) patients. Dynamic lactate assessment, for example, normalized lactate load, has been a better prognosis predictor than single lactate value in septic shock. Our objective was to investigate the correlation between normalized lactate load and in-hospital mortality in patients with CS.
METHODS: Data were extracted from the Medical Information Mart for Intensive Care (MIMIC)-IV database. The calculation of lactate load involved the determination of the cumulative area under the lactate curve, while normalized lactate load was computed by dividing the lactate load by the corresponding period. Receiver Operating Characteristic (ROC) curves were constructed, and the evaluation of areas under the curves (AUC) for various parameters was performed using the DeLong test.
RESULTS: Our study involved a cohort of 1932 CS patients, with 687 individuals (36.1%) experiencing mortality during their hospitalization. The AUC for normalized lactate load demonstrated significant superiority compared to the first lactate (0.675 vs. 0.646, P < 0.001), maximum lactate (0.675 vs. 0.651, P < 0.001), and mean lactate (0.675 vs. 0.669, P = 0.003). Notably, the AUC for normalized lactate load showed comparability to that of the Sequential Organ Failure Assessment (SOFA) score (0.675 vs. 0.695, P = 0.175).
CONCLUSION: The normalized lactate load was an independently associated with the in-hospital mortality among CS patients.
Procedure for obtaining pregn 1.4 dienos. It consists of a process of microbiological fermentation in which a microorganism of species is used as a cultivation. Corynebacterium simplex and corynebacterium hoagic. They are used as stereoides of a composite form of general formula (I). The nutrient medium may be sodium phosphate or 0.2 m potassic phosphate. The temperature of the process is comprised between 20g and 40g and the reaction time rocks between 3 and 48 hours. Anti-inflammatory *formula* (Machine-translation by Google Translate, not legally binding)
The head of the baby's bed will be raised at an angle of 45 degrees and before the procedure, 2 ml of breast milk will be given by the research clinical nurse with the help of a sterile injector, provided that each baby is breast milk, and then the mother will be in direct skin-to-skin contact with the mother's breast, with only the diaper under the baby in the baby adaptation room. It will be placed on the mother's chest at an angle of 60 degrees. The mother will be instructed not to make additional movements such as stroking, talking, feeding and shaking her baby. After 10 minutes of kangaroo mother care, heel blood collection will be performed and after the procedure, kangaroo mother care will continue for 2 more minutes. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the "Physiological Parameters Measurement Form".
Postoperative delayed gastric emptying is a prevalent complication following surgical procedures, imposing heavy physical and financial burdens on patients. However, current treatment options remain suboptimal. In recent years, an increasing number of studies have highlighted that the gut microbiota and its metabolites are closely associated with postoperative complications. Various factors can disrupt the gut microbiome after surgery. This review discusses the potential mechanisms by which the gut microbiota and their metabolites may contribute to the pathogenesis of postoperative delayed gastric emptying. However, the current knowledge base is limited in terms of fully understanding the exact mechanisms involved. It is therefore evident that further research is required to fully elucidate the role of the gut microbiome in postoperative delayed gastric emptying, with the aim of uncovering new possibilities for preventive measures and therapeutic treatments.
FIELD: medicine. 
     SUBSTANCE: method involves carrying out remote gamma-therapy for treating the pancreas in individual mode. Tumor size being small, biaxial or monoaxial double-sector rotation is applied. The tumor size being greater than 10 cm, static multiple field mode is used with fractional dose supply in 2 Gr large portions twice a day with 4-5 h long pause. The total focal dose is equal to 24-28 Gr. The treatment course is repeated at a dose of 52-56 Gr after two weeks long relief pause. 2-3 weeks later, autohemochemotherapy is administered. Blood is taken in portions of 80 ml into 3 flasks with standard preservative agent. 5-fluorouracyl is introduced into the first flask keeping to concentration of 600 mg/m 2 . Doxorubicine is introduced into the second flask in the amount of 30 mg/m 2 . Mytomycine C is introduced into the third flask to provide10 mg/m 2 . The flasks are incubated at 37° C during 45 min and blood reinfusion is carried out with cytostatic reagents in known way. 80 ml of patient blood is taken at the eighth day into a flask containing preservative agent. 5-fluorouracyl is added in the amount of 600 mg/m 2 . Incubation at 37° C is carried out during 45 min and the blood is injected to the patient. Patient blood is taken into two flasks at the twenty seventh day in the amount of 80 ml in each flask mixed with a standard preservative agent. 5-fluorouracyl is added to the first flask in the amount of 600 mg/m 2 . Doxorubicine is introduced into the second flask in the amount of 30 mg/m 2 . The flasks are incubated at 37° C during 45 min and blood reinfusion is carried out in the succession order pointed out. 80 ml of patient blood is taken at the thirty sixth day into one flask containing a standard preservative agent. 5-fluorouracyl is added in the amount of 600 mg/m 2 . Incubation at 37° C is carried out during 45 min and the blood is injected to the patient. Chemotherapy preparations are given in the following quantities per course: Mytomycine C - 10 mg/m 2 , Doxorubicine - 60 mg/m 2 , 5-fluorouracyl - 2400mg/ m 2 . 
     EFFECT: enhanced effectiveness in reducing tumor size; high analgesic efficiency; reduced risk of complications caused by radiation and chemotherapy. 
     2 dwg